International Workshop for Human Brain Banking & the 2nd National Human Brain Banking Continuous Education Program
In order to promote clinical and basic research on neurological disorders, to enhance human brain tissues based scientific researches in China, and to improve clinical diagnosis and treatment standards for rare and refractory neurological disorders, the International Workshop for Human Brain Banking will be held on Nov. 25th to 27th, 2020. Meanwhile, the National Continuous Education Program on Human Brain Banking will be conducted (ID: 2020-03-07-222), and class I credit of 6 points will be awarded.
The workshop will last for three days and cover four main topics: 1) Human brain banking and Neurology, 2) Human brain banking and Neuroscience, 3) Human brain banking and Social science, 4) Rare neurological diseases and precision medicine. The workshop will invite distinguished neuroscientists from the United States, Australia, Denmark and other countries with related expertise, as well as excellent neurologists and sociological experts from China, to give systematic lectures and clinical pathological discussions on four cases.
National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Chinese Association for Prevention and Treatment of Alzheimer's Disease, Beijing, China
China National Continuous Education Program (2020-03-07-222)
National Natural Science Foundation of China (82071417)
Partial Invited Speakers
Dr Claire Shepherd
The Director of the Sydney Brain Bank at Neuroscience Research Australia.
Dr. Shepherd trained in neuroscience and completed her PhD in Alzheimer’s disease at the University of Sheffield, UK. After completing her PhD she relocated to Sydney to pursue her interest in the neuropathology of dementia. Soon after her move, Claire was awarded the prestigious Rolf Edgar Lake Fellowship from the University of Sydney and subsequently directed a National Health and Medical Research Council (NHMRC) project grant as CIA. In 2000 Claire was awarded the inaugural Franz Nissl Young Investigator Prize in Neuroscience in recognition of achievements in her early post-doctoral years. She now runs the Sydney Brain Bank, which is a research facility that collects, characterises and stores brain tissue for research into neurodegenerative disease. Claire is also the Director of the Shepherd Dementia Research Laboratory at NeuRA and lead investigator on the NeuRA Volunteers Brain Donor Program – a longitudinal research program aimed at investigating the clinical consequences of the cellular changes that occur during ageing. In October 2019, Claire received funding from the Brain Foundation for a new research program that will investigate the presence of chronic traumatic encephalopathy (CTE) in the brain tissue of a large population of well-characterised individuals held by the Sydney Brain Bank and determine any association with repetitive traumatic brain injury exposure. On 27 November, the National Rugby League (NRL) announced support of a new donor program for former players to the Sydney Brain Bank. This is part of Claire’s newest research into how sports-related brain changes impact on a player’s quality of life.
Poul Henning Jensen, MD, PhD
Professor and Core Group Leader at The Danish Research Institute of Translational Neuroscience (DANDRITE) and the Department of Bio-medicine, Aarhus University, Denmark.
Dr. Jensen was received his MD from the University of Aarhus where he completed his medical internship. He obtained his PhD from Aarhus University on studies in structure function of a serine proteinase inhibitor. He worked in the departments of physiology, medical biochemistry and biomedicine at Aarhus University. He has been professor of medical biochemistry there since 2004. He was visiting scientist from1997-98 at European Molecular Biology Organization in Heidelberg, Germany, and the head of department of medical biochemistry 2001-2011.
His focus of studies since 1996 has been the normal biological role of alpha-synuclein and how it contributes to the neurodegeneration taking place in Parkinson's disease and related brain disorders. He is currently focusing on disease modelling in cells and pre-clinical models, biomarkers studies and development of reagents. He has published extensively in this field and partaken in organizing several workshops related to the area. He is a partner in European Union funded research networks, and receiving funding from MJFF on Parkinson’s disease.
Professor Liz Milward
Professor, School of Biomedical Sciences and Pharmacy (Medical Genetics), University of Newcastle (UON)
Prof. Milward has expertise in neurodegenerative, cerebrovascular and myelin disorders with past fellowships at US NIH, Johns Hopkins Neurology and USYD Dept. of Medicine and 15+y experience in high level strategic planning/implementation and management of personnel, resources, budgets and large volume data. This spans early experience as CI-A of a team of geriatricians, medical physicists and public health biostatisticians on successfully completed epidemiological, clinical, neuroimaging and lab studies of iron and Alzheimer’s disease in over 1,000 participants (NHMRC 254594) to leading productive multidisciplinary international teams including University College London members from the UK Brain Expression Consortium. Her trainees receive prestigious national and international awards e.g. 2016 Australian Neuroscience Society Best Paper PHD/Early Career. Her election as Deputy President, UON Academic Senate (ending 2021 after max 4 terms) also testifies to her exceptional leadership capabilities.
Dr. Wen-Quan Zou
Professor of Pathology with tenure and Associate Director of the National Prion Disease Pathology Surveillance Center at the Case Western Reserve University
Dr. Wen-Quan Zou received his medical degree from Jiangxi Medical College, his M.Sc. from Tongji Medical University, and his Ph.D. from Shanghai Medical University.
Dr. Zou’s research focus is in the areas of protein aggregation in the conformational diseases especially on the physiological and pathologic prion proteins (PrPC and PrPSc) in prion diseases (PrD) as well as on neurotoxic amyloid β (Aβ) and tau in Alzheimer disease (AD) and α-synuclein in Parkinson’s disease (PD). The co-existence of PrPC and PrPSc in the central nervous system is a prerequisite for PrD, a group of fatal transmissible neurodegenerative diseases such as Creutzfeldt-Jakob disease (CJD) in humans. His laboratory is the first to demonstrate that small amounts of insoluble aggregates and protease-resistant conformers of PrP called insoluble PrPC (iPrPC) are present in normal human brains (Yuan et al., 2006). The discovery of this new isoform of PrPC may conceivably open a new frontier for investigating the pathogenesis of PrD. Remarkably, the Zou laboratory revealed for the first time that iPrPC is the major PrP species that interacts with Aβ in AD and that human PrP exhibits two types of Aβ-binding sites on in terms of its specificity for Aβ42 (Zou et al., 2011). Recently, the Zou lab has demonstrated that the infectious prions are present in the skin of CJD patients (Orru et al., 2017) and they are detectable much earlier than brain damage and clinical signs in prion-infected rodents (Wang et al., 2019), which provides the first proof-of-concept evidence that skin prions can be a biomarker for preclinical diagnosis of prion diseases. Currently, the Zou lab is extending these findings to other common neurodegenerative diseases including PD (Wang et al., 2020) and AD with ultrasensitive real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) assays, which may develop highly sensitive and specific skin-based diagnostic tools for less-invasive and early diagnosis for these neurodegenerative diseases.
A/Prof. Antony Cooper
Garvan Institute of Medical Research
Research Director: Australian Parkinson’s Mission
UNSW-Sydney: St Vincent’s Clinical School
Antony completed a PhD at McGill University working on membrane trafficking, and post-doctoral studies at the University of Oregon involving both protein splicing and proteostasis/protein quality control in the endoplasmic reticulum (ER). As an Assistant Professor at the University of Missouri his interests evolved to protein misfolding, ER stress and oxidative stress, factors common to many neurodegenerative diseases.
A/Prof. Antony Cooper is a cell and molecular biologist / geneticist with strong interests in elucidating how cellular dysfunction results in human diseases, with a specific interest in neurodegenerative disease such as Parkinson’s Disease. His research on neurodegenerative diseases focuses on understanding the basis of Parkinson’s Disease.
As Research Director of the Australian Parkinson’s Mission, Antony is applying a precision-medicine framework to genomically stratify Parkinson’s patients to enrich for individuals best suited to the therapeutic being clinically tested to slow/stop disease progression.
A/Prof. Cooper will give a lecture entitled with The Australian Parkinson’s Mission: Precision medicine approaches in Parkinson's Disease in this workshop.
●Professor of Geriatrics, South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales
●Professor of Geriatrics, Faculty of Medicine, Western Sydney University
●Director of aged care and rehabilitation at Bankstown-Lidcombe Hospital, Sydney
●Honorary Professor Beijing Hospital
●International expert, Academic Committee, National Centre of Gerontology and National Clinical Research Centre for Geriatric Medicine
●Honorary Mentor of Geriatricians at Ruijin Hospital, Beijing Hospital and Beijing Geriatric Hospital
●Author of “Chan’s Practical Geriatrics” in collaboration with Peking Union Medical College
●Over 150 publications in the peer-reviewed journals e.g. New England Journal of Medicine
●Editorial board: Asian Journal of Gerontology & Geriatrics (International advisor), ISRN Geriatrics, Clinical and Experimental Pharmacology and Physiology, Geriatrics,
Hong Kong Medical Journal (International Editorial Advisory Board), Aging Medicine
●Obtained 10 million dollars of research grants including 2 NHMRC project grants